Skip to content
CancerIndex

Publication

The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC).

Hye Sung Kim, Li Zhang, J Nicholas Bodor, Margie L Clapper, Hossein Borghaei, Martin J Edelman, Yunyun Zhou, Mitchell Cheung, Joseph Treat

Lung cancer (Amsterdam, Netherlands)Oct 1, 2026PMID 42660014doi:10.1016/j.lungcan.2026.109582 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 13, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260913-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

BACKGROUND: Osimertinib is a standard therapy for EGFR-mutant NSCLC. However, markers to better identify those at risk for poor outcomes are needed. This is the largest study to date evaluating the impact of EGFR subtype combined with TP53 co-mutation status on survival endpoints with front-line…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.